索拉非尼不良反应对其疗效的预测价值

Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma

《肝脏病学》(Hepatology)杂志2011年刊登了一项有关索拉非尼治疗中期肝细胞癌的前瞻性队列研究。这项研究发现那些在大于70%的疗程中主要采用半剂量治疗的患者中位生存时间长于全剂量治疗的患者。这一现象引起了我们的关注,并对此做了进一步的分析。我们认为,索拉非尼药物不良反应具有预测其疗效的价值。

A prospective multi-center cohort study entitled Field-practice study of sorafenib therapy for hepatocellular carcinoma： a prospective multicenter study in Italy was published in Hepatology in 2011. We read with great interest the recent study providing stronger evidence of the treatment of sorafenib in hepatocellular carcinoma patients with intermediate stage. The authors reported that the patients receiving a half-dose of sorafenib for 〉70% of the treatment period had a longer median survival than those who maintained on a full dose （21.6 vs 9.6 months）. We considered that the patients in this study who experienced adverse events responded better to sorafenib than those who did not. Thus we wrote a correspondence to the journal proposing that the drug-related adverse events might presumably predict the efficacy of sorafenib therapy.